Video

NIH director updates study enrolling one million participants


 

REPORTING FROM ENDO 2019

NEW ORLEANS – It is not too late to enroll your patients or yourself into the largest longitudinal cohort study ever initiated, according to Francis S. Collins, MD, PhD, who is director of the National Institutes of Health (NIH).

Since May 2018, when it was initiated, the NIH-funded All of Us Research Program has already enrolled 200,000 of the planned goal of one million participants in the United States. Of these, approximately half have already provided baseline demographics and health information as well as their consent to use the slew of health data that is being collected.

“The only way to do this kind of thing is to have data – a lot of it,” said Dr. Collins, explaining the premise of the All of Us Research Program in an interview conducted at the annual meeting of the Endocrine Society.

The data are not limited to medical records: Blood samples, whole genome sequencing, wearable activity monitors, and subject-completed questionnaires are among a long list of sources of information to be collected from participants, who are expected to be followed indefinitely.

According to Dr. Collins, who delivered a plenary address at the meeting, these data will become more valuable over time, one of the most important goals of this study is to prepare the way for precision medicine. As opposed to the traditional one-size-fits-all approach to treating disease, he believes that this large dataset will allow researchers to understand differences in common diseases at the individual level.

In relation to endocrinology, Dr. Collins said that a cohort of one million participants would be expected to have close to 100,000 individuals with diabetes mellitus.

“This is going to be transformative,” said Dr. Collins, who emphasized that the enrollment is specifically designed to capture participants from diverse ethnic and racial groups.

All of the data collected will be made broadly available to research initiatives of all kinds, many of which have not yet even been envisioned.

Information on enrollment is available on line: joinallofus.org.

Recommended Reading

ICU admissions raise chronic condition risk
MDedge Internal Medicine
FDA approves label extension for dapagliflozin
MDedge Internal Medicine
Dermatologists name isobornyl acrylate contact allergen of the year
MDedge Internal Medicine
Behavioral intervention improves physical activity in patients with diabetes
MDedge Internal Medicine
HCV treatment with DAA regimens linked to reduced diabetes risk
MDedge Internal Medicine
How much difference will Eli Lilly’s half-price insulin make?
MDedge Internal Medicine
Semaglutide plus SGLT2 inhibitors improves glycemic control in type 2 diabetes
MDedge Internal Medicine
Newer antihyperglycemic drugs have distinctive CV, kidney benefits
MDedge Internal Medicine
ACC, AHA release first cardiovascular disease primary prevention guideline
MDedge Internal Medicine
Long-term metformin offsets diabetes in patients with higher glucose/HbA1c, history of gestational diabetes
MDedge Internal Medicine